poseida therapeutics, inc. is currently developing car-t and gene therapy products for cancer and orphan diseases. spinout of transposagen biopharmaceuticals early this year, poseida is also collaborating with j&j’s janssen to develop allogeneic car-t therapies against cancer. poseida boasts best-in-class genome engineering capabilities for effectively silencing target genes or inserting therapeutic genes and/or technologies. proprietary tools include piggybac™ dna modification system, nextgen™ crispr, xtn™ talen and footprint-free™ gene editing system, which are clean (synthetic and virus-free) and can be surgically precise. poseida aims to shuttle the first car-t and gene therapy product candidates into phase i clinical trials in early 2016. poseida is now hiring and searching for ambitious and motivated scientists desiring a fast-paced work environment with diverse research opportunities in the field of cellular and gene therapy.
Company profile
Ticker
PSTX
Exchange
Website
CEO
Eric Ostertag
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Vindico NanoBioTechnology, LLC ...
PSTX stock data
Latest filings (excl ownership)
8-K
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
17 Apr 24
S-3
Shelf registration
8 Apr 24
8-K
Regulation FD Disclosure
8 Apr 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
7 Mar 24
S-8
Registration of securities for employees
8 Feb 24
8-K
Departure of Directors or Certain Officers
4 Jan 24
8-K
Regulation FD Disclosure
11 Dec 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023
9 Nov 23
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.50 mm | 25.50 mm | 25.50 mm | 25.50 mm | 25.50 mm | 25.50 mm |
Cash burn (monthly) | 8.14 mm | 11.61 mm | 12.07 mm | 11.40 mm | (no burn) | 5.09 mm |
Cash used (since last report) | 54.21 mm | 77.35 mm | 80.45 mm | 75.97 mm | n/a | 33.88 mm |
Cash remaining | -28.71 mm | -51.85 mm | -54.95 mm | -50.47 mm | n/a | -8.38 mm |
Runway (months of cash) | -3.5 | -4.5 | -4.6 | -4.4 | n/a | -1.6 |
Institutional ownership, Q3 2023
62.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 86 |
Opened positions | 11 |
Closed positions | 20 |
Increased positions | 29 |
Reduced positions | 23 |
13F shares | Current |
---|---|
Total value | 105.02 bn |
Total shares | 60.29 mm |
Total puts | 11.30 k |
Total calls | 86.60 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
FMR | 13.04 mm | $31.03 bn |
Malin Life Sciences | 9.19 mm | $119.54 mm |
Pentwater Capital Management | 5.98 mm | $14.22 bn |
Novartis Pharma | 5.91 mm | $64.81 mm |
BLK Blackrock | 5.05 mm | $12.03 bn |
Silverarc Capital Management | 3.57 mm | $8.49 bn |
Vanguard | 2.64 mm | $6.28 bn |
Millennium Management | 2.55 mm | $6.08 bn |
Geode Capital Management | 1.42 mm | $3.38 bn |
STT State Street | 1.23 mm | $2.92 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Apr 24 | Syed Ali-aamir Rizvi | Common Stock | Grant | Acquire A | No | No | 0 | 185,000 | 0.00 | 185,000 |
1 Apr 24 | Syed Ali-aamir Rizvi | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 3.1 | 250,000 | 775.00 k | 250,000 |
1 Mar 24 | Johanna Mylet | Common Stock | Payment of exercise | Dispose F | No | No | 4.13 | 18,091 | 74.72 k | 246,283 |
1 Mar 24 | Johanna Mylet | Common Stock | Grant | Acquire A | No | No | 0 | 80,743 | 0.00 | 264,374 |
1 Mar 24 | Johanna Mylet | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.13 | 111,700 | 461.32 k | 111,700 |
1 Mar 24 | Gergen Mark J | Common Stock | Payment of exercise | Dispose F | No | No | 4.13 | 34,157 | 141.07 k | 651,291 |
1 Mar 24 | Harry J Leonhardt | Common Stock | Payment of exercise | Dispose F | No | No | 4.13 | 16,306 | 67.34 k | 214,640 |
1 Mar 24 | Harry J Leonhardt | Common Stock | Grant | Acquire A | No | No | 0 | 80,743 | 0.00 | 230,946 |
1 Mar 24 | Harry J Leonhardt | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 4.13 | 111,700 | 461.32 k | 111,700 |
News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
16 Apr 24
12 Health Care Stocks Moving In Monday's After-Market Session
15 Apr 24
Poseida Therapeutics Presents New Phase 1 Data At AACR 2024 Supporting Potential Of P-BCMA-ALLO1 Allogeneic CAR-T Therapy To Benefit Broad Range Of Patients With Multiple Myeloma
8 Apr 24
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
11 Mar 24
12 Health Care Stocks Moving In Monday's Intraday Session
11 Mar 24
Press releases
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
18 Apr 24
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
17 Apr 24
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
8 Apr 24
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1 Apr 24
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
25 Mar 24